Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Source: 
BioSpace
snippet: 

Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.